Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and Female subjects between 18-65 years of age, with diagnosis of major depressive disorder with or without anxious distress~* Current depressive episode must be at least 8 weeks in duration~Exclusion Criteria:~* Subjects with a history of Neuroleptic Malignant Syndrome or Serotonin Syndrome~* Subjects who report an inadequate response to more than 3 antidepressant treatments in the current episode~* Subjects with a current Axis I diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole + ADT (Type: EXPERIMENTAL): Brexpiprazole + ADT
- Placebo + ADT (Type: PLACEBO_COMPARATOR): Placebo + ADT

Based on this trial design, predict the completion outcome and termination type (if applicable).